噬菌体治疗耐碳青霉烯鲍曼不动杆菌合并铜绿假单胞菌 肺部感染的病例报道

doi:10.19871/j.cnki.xfcrbzz.2022.02.015

新发传染病电子杂志 ›› 2022, Vol. 7 ›› Issue (2): 71-75.doi: 10.19871/j.cnki.xfcrbzz.2022.02.015

噬菌体治疗耐碳青霉烯鲍曼不动杆菌合并铜绿假单胞菌肺部感染的病例报道

陈培芬¹, 孔英君¹, 文思¹, 顾晓雯¹, 周央¹, 谭新², 马迎飞², 卢洪洲¹

1.深圳市第三人民医院呼吸内科,国家感染性疾病临床医学研究中心,南方科技大学第二附属医院,广东深圳 518112;
2.深圳合成基因组学重点实验室,广东省合成基因组学重点实验室,中国科学院定量工程生物学重点实验室,深圳合成生物学研究所,中国科学院深圳先进技术研究院,广东深圳 518055

收稿日期:2022-02-14 出版日期:2022-05-31 发布日期:2022-07-07
通讯作者: 马迎飞,yingfei.ma@siat.ac.cn;卢洪洲,Email:luhongzhou@fudan.edu.cn

A case report of phage therapy against lung infection caused by Carbapenem-resistant Acinetobacter baumannii and Carbapenem-resistant Pseudomonas aeruginosa

Chen Peifen¹, Kong Yingjun¹, Wen Si¹, Gu Xiaowen¹, Zhou Yang¹, Tan Xin², Ma Yingfei², Lu Hongzhou¹

1. The Third People's Hospital of Shenzhen and National Clinical Research Centre for Infectious Diseases, The Second Affiliated Hospital of Southern University of Science and Technology, Guangdong Shenzhen 518112, China;
2. Shenzhen Key Laboratory of Synthetic Genomics, Guangdong Provincial Key Laboratory of Synthetic Genomics, CAS Key Laboratory of Quantitative Engineering Biology, Shenzhen Institute of Synthetic Biology, Shenzhen Institutes of Advanced Technology, Chinese Academy of Sciences, Shenzhen 518055, China

Received:2022-02-14 Online:2022-05-31 Published:2022-07-07

摘要/Abstract

摘要： 82岁男性患者,因反复肺部感染半年入院。患者既往有阿尔茨海默病史。本次入院前多次痰培养为耐碳青霉烯鲍曼不动杆菌和耐碳青霉烯铜绿假单胞菌,使用包括替加环素在内的多种抗生素,患者痰细菌培养未转阴、肺部感染未改善。入院后予鲍曼不动杆菌噬菌体加铜绿假单胞菌噬菌体鸡尾酒疗法,每天2次雾化吸入,疗程分别为10d和19d;联合静脉滴注替加环素、哌拉西林他唑巴坦和阿米卡星。患者耐受良好,痰培养未见鲍曼不动杆菌生长,痰中铜绿假单胞菌荷菌量减少,临床症状和胸部X线片提示肺部感染明显好转。

关键词: 噬菌体, 耐碳青霉烯鲍曼不动杆菌, 耐碳青霉烯铜绿假单胞菌, 肺部感染, 耐药细菌

Abstract: One 82-year-old male patient suffering from Alzheimer's disease was admitted to the hospital due to repeated pulmonary infection in the past half-year. Carbapenem-resistant Acinetobacter baumannii (CRAB）and Carbapenem-resistant Pseudomonas aeruginosa(CRPA）were cultured in the sputum so he was treated with a variety of antibiotics including tigecycline before admission. However, Pulmonary infection and sputum culture of CRAB and CRPA did not show any sign of improvement. After admission, a single-phage preparation for CRAB and a two-phage cocktail preparation for CRPA was nebulized twice daily, combined with intravenous administration of tigecycline, piperacillin-tazobactam and amikacin. Phages for CRAB lasted for 10 days and phages for CRPA lasted for 19 days in total. The treatment was well tolerated and resulted in clearance of the CRAB and reduction of CRPA. Clinical signs and chest X-ray indicated that the pulmonary infection was improved gradually.

Key words: Phage, Carbapenem-resistant Acinetobacter baumannii, Carbapenem-resistant Pseudomonas aeruginosa, Pulmonary infection, Drug-resistant bacteria

陈培芬, 孔英君, 文思, 顾晓雯, 周央, 谭新, 马迎飞, 卢洪洲. 噬菌体治疗耐碳青霉烯鲍曼不动杆菌合并铜绿假单胞菌肺部感染的病例报道[J]. 新发传染病电子杂志, 2022, 7(2): 71-75.

Chen Peifen, Kong Yingjun, Wen Si, Gu Xiaowen, Zhou Yang, Tan Xin, Ma Yingfei, Lu Hongzhou. A case report of phage therapy against lung infection caused by Carbapenem-resistant Acinetobacter baumannii and Carbapenem-resistant Pseudomonas aeruginosa[J]. Electronic Journal of Emerging Infectious Diseases, 2022, 7(2): 71-75.

参考文献

[1] 梁庄万,张群,蒋秋燕,等.重症监护室老年感染性疾病病原菌分布及耐药性分析[J/CD].新发传染病电子杂志,2021, 6(2): 96-99.
[2] WONG D,NIELSEN TS, BONOMO RA, et al.Clinical and Pathophysiological Overview of Acinetobacter Infections: a Century of Challenges[J]. Clin Microbiol Rev, 2017,30(1):409-447.
[3] TACCONELLI E, CARRARA E, SAVOLDI A, et al.Discovery, research, and development of new antibiotics: the WHO priority list of antibiotic-resistant bacteria and tuberculosis[J]. Lancet Infect Dis, 2018, 18(3): 318-327.
[4] COHAN FM, ZANDI M, TURNER PE.Broadscale phage therapy is unlikely to select for widespread evolutionn of baterial cresistance to virus infection[J]. Virus Evol, 2020, 6(2): veaa060.
[5] YIN S, HUANG G, ZHANG Y, et al.Phage Abp1 rescues human cells and mice from infection by pan-drug resistant Acinetobacter baumannii[J]. Cell Physiol Biochem, 2017, 44(6):2337-2345.
[6] WITTEBOLE X, ROOCK DE, OPAL SM.A historical overview of bacteriophage therapy as an alternative to antibiotics for the treatment of bacterial pathogens[J]. Virulence, 2014, 5(1): 226-235.
[7] SHEN GH, WANG JL, WEN FS, et al.Isolation and characterization of φkm18p, a novel lytic phage with therapeutic potential against extensively drug resistant Acinetobacter baumannii[J]. PLoS One, 2012, 7(10): e46537.
[8] EUROPEAN CENTRE FOR DISEASE PREVENTION AND CONTROL. Rapid risk assessment: carbapenem-resistant Acinetobacter baumannii in healthcare settings-8 December 2016.[EB/OL]. http://ecdc.europa.eu/publications-data/rapidrisk-assessment-carbapenem-resistant-acinetobacter-bau-manniihealthcare.
[9] 周华,俞云松,周建英.多重耐药鲍曼不动杆菌感染治疗进展[J]. 中华内科杂志, 2015,54( 7) : 644-647.
[10] SATO Y,UNNO Y,KAWAKAMI S,et al.Virulence characteristics of Acinetobacter baumannii clinical isolates vary with the expression levels of omps[J]. J Med Microbiol, 2017,66( 2) : 203-212.
[11] SCHOOLRY RT, BISWAS B, GILL JJ, et al.Development and use of personalized bacteriophage-based therapeutic cocktails to treat a patient with a disseminated resistant Acinetobacter baumannii infection[J]. Antimicrob Agents Chemother, 2017, 61(10): e00954-e00917.
[12] TAN X, CHEN H, ZHANG M, et al.Clinical Experience of Personalized Phage Therapy Against Carbapenem-Resistant Acinetobacter baumannii Lung Infection in a Patient With Chronic Obstructive Pulmonary Disease[J]. Front Cell Infect Microbiol, 2021, 11: 631585.
[13] WU N, DAI J, GUO M, et al.Pre-optimized phage therapy on secondary Acinetobacter baumannii infection in four critical COVID-19 patients[J]. Emerg Microbes Infect, 2021, 10(1):612-618.
[14] 林佳冰, 高晓东, 崔扬文,等. 上海市90所医院临床病原学标本送检及耐药菌检出现状分析[J].中华医院感染学杂志, 2018, 28(8):1162-1165.
[15] KALIL AC, METERSKY ML, KLOMPAS M, et al.Executive Summary: Management of Adults With Hospital-acquired and Ventilator-associated Pneumonia: 2016 Clinical Practice Guidelines by the Infectious Diseases Society of America and the American Thoracic Society[J]. Clin Infect Dis, 2016, 63(5):575-582.
[16] PENA C, CABOT G, GOMEZ-ZORRILLA S, et al, Spanish Network for Research in Infectious Diseases (REIPI). Influence of virulence geno-type and resistance profile in the mortality of Pseudomonas aeruginosa bloodstream infections[J]. Clin Infect Dis, 2015, 60:539-548.
[17] WALKTY A, LAGACE-WIENS P, ADAM H, et al.Antimicrobial susceptibility of 2906 Pseudomonas aeruginosa clinical isolates obtained from patients in Canadian hospitals over a period of 8 years: Results of the Canadian Ward surveillance study (CANWARD), 2008-2015[J]. Diagn Microbiol Infect Dis, 2017, 87:60-63.
[18] SADER HS, CASTANHEIRA M, DUNCAN LR, et al.Antimicrobial susceptibility of Enterobacteriaceae and Pseudomonas aeruginosa isolates from United States medical centers stratified by infection type: results from the International Network for Optimal Resistance Monitoring (INFORM) surveillance program[J]. Diagn Microbiol Infect Dis, 2018, 92: 69-74.
[19] US DEPARTMENT OF HEALTH, SERVICES H. Antibiotic resistance threats in the United States, 2013[EB/OL]. [2013-12-18]. https://www.michigan.gov/-/media/Project/Websites/mdhhs/Folder2/Folder92/Folder1/Folder192/AR_Key_Points_for_Partners.pdf?rev=6712581e77fa4cebad8.
[20] WORLD HEALTH ORGANIZATION.Prioritization of Pathogens to Guide Discovery, Research and Development of New Antibiotics for Drug-Resistant Bacterial Infections, Including Tuberculosis[M]. Geneva: World Health Organization, 2017.
[21] JAULT P, LECLERC T, JENNES S, et al.Efficacy and tolerability of a cocktail of bacteriophages to treat burn wounds infected by Pseudomonas aeruginosa (PhagoBurn): a randomised, controlled, double-blind phase 1/2 trial[J]. Lancet Infect Dis, 2019, 19(1): 35-45.
[22] FURR CL, LEHMAN SM, MORALES SP, et al.P084 bacteriophage treatment of multidrug-resistant Pseudomonas aeruginosa pneumonia in a cystic fibrosis patient[J]. Journal of Cystic Fibrosis, 2018,17(S3): S83.
[23] MADDOCKS S, FABIJAN AP, HO J, et al.Bacteriophage therapy of ventilator-associated pneumonia and empyema caused by Pseudomonas aeruginosa[J]. Am J Respir Crit Care Med, 2019,200(9):1179-1181
[24] WRIGHT A, HAWKINS CH, ANGGARD EE, et al.A controlled clinical trial of a therapeutic bacteriophage preparation in chronic otitis due to antibiotic-resistant Pseudomonas aeruginosa; a preliminary report of efficacy[J]. Clin Otolaryngol, 2009, 34(4): 349-357.
[25] 郭孝兰,李永伟.铜绿假单胞菌耐药机制与生物被膜相关性研究进展[J/CD].新发传染病电子杂志, 2017, 2(3):188-191.
[26] CHAUDHRY WN, CONCEPCION-ACEVEDO J, PARK T, et al.Synergy and order effects of antibiotics and phages in killing Pseudomonas aeruginosa biofilms[J]. PLoS ONE, 2017, 12: e0168615.
[27] OECHSLIN F, PICCARDI P, MANCINI S, et al.Synergistic interaction between phage therapy and antibiotics clears Pseudomonas aeruginosa infection in endocarditis and reduces virulence[J]. J Infect Dis, 2016, 215:703-712.

噬菌体治疗耐碳青霉烯鲍曼不动杆菌合并铜绿假单胞菌肺部感染的病例报道

A case report of phage therapy against lung infection caused by Carbapenem-resistant Acinetobacter baumannii and Carbapenem-resistant Pseudomonas aeruginosa

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 1

编辑推荐

Metrics

本文评价

噬菌体治疗耐碳青霉烯鲍曼不动杆菌合并铜绿假单胞菌 肺部感染的病例报道

A case report of phage therapy against lung infection caused by Carbapenem-resistant Acinetobacter baumannii and Carbapenem-resistant Pseudomonas aeruginosa

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 1

编辑推荐

Metrics

本文评价

噬菌体治疗耐碳青霉烯鲍曼不动杆菌合并铜绿假单胞菌肺部感染的病例报道